Consolidated Statements of Stockholders' Equity - USD ($)	Over-Allotment Option [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Over-Allotment Option [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Over-Allotment Option [Member] Preferred Stock [Member]	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member] AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Private Placement [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Consulting Agreement One [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consulting Agreement One [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Consulting Agreement One [Member] Preferred Stock [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member] Retained Earnings [Member]	Consulting Agreement One [Member] AOCI Attributable to Parent [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consulting Agreement Two [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Consulting Agreement Two [Member] Preferred Stock [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member] Retained Earnings [Member]	Consulting Agreement Two [Member] AOCI Attributable to Parent [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Investor Relations Consultant [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Investor Relations Consultant [Member] Preferred Stock [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member] Retained Earnings [Member]	Investor Relations Consultant [Member] AOCI Attributable to Parent [Member]	Investor Relations Consultant [Member]	Consultant Contract One [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consultant Contract One [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Consultant Contract One [Member] Preferred Stock [Member]	Consultant Contract One [Member] Common Stock [Member]	Consultant Contract One [Member] Additional Paid-in Capital [Member]	Consultant Contract One [Member] Retained Earnings [Member]	Consultant Contract One [Member] AOCI Attributable to Parent [Member]	Consultant Contract One [Member]	Consultant Contract Two [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Consultant Contract Two [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Consultant Contract Two [Member] Preferred Stock [Member]	Consultant Contract Two [Member] Common Stock [Member]	Consultant Contract Two [Member] Additional Paid-in Capital [Member]	Consultant Contract Two [Member] Retained Earnings [Member]	Consultant Contract Two [Member] AOCI Attributable to Parent [Member]	Consultant Contract Two [Member]	Contract with TumorGenesis [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Contract with TumorGenesis [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Contract with TumorGenesis [Member] Preferred Stock [Member]	Contract with TumorGenesis [Member] Common Stock [Member]	Contract with TumorGenesis [Member] Additional Paid-in Capital [Member]	Contract with TumorGenesis [Member] Retained Earnings [Member]	Contract with TumorGenesis [Member] AOCI Attributable to Parent [Member]	Contract with TumorGenesis [Member]	Helomics Holding Corp. [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Helomics Holding Corp. [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Helomics Holding Corp. [Member] Preferred Stock [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member] Retained Earnings [Member]	Helomics Holding Corp. [Member] AOCI Attributable to Parent [Member]	Helomics Holding Corp. [Member]	Series E Warrants [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Series E Warrants [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Series E Warrants [Member] Preferred Stock [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member] Retained Earnings [Member]	Series E Warrants [Member] AOCI Attributable to Parent [Member]	Series E Warrants [Member]	Re-priced Warrants [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Re-priced Warrants [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Re-priced Warrants [Member] Preferred Stock [Member]	Re-priced Warrants [Member] Common Stock [Member]	Re-priced Warrants [Member] Additional Paid-in Capital [Member]	Re-priced Warrants [Member] Retained Earnings [Member]	Re-priced Warrants [Member] AOCI Attributable to Parent [Member]	Re-priced Warrants [Member]	Bridge Loan Warrants [Member] Preferred Stock [Member]	Bridge Loan Warrants [Member] Common Stock [Member]	Bridge Loan Warrants [Member] Additional Paid-in Capital [Member]	Bridge Loan Warrants [Member] Retained Earnings [Member]	Bridge Loan Warrants [Member] AOCI Attributable to Parent [Member]	Bridge Loan Warrants [Member]	Note Payable Warrants [Member] Preferred Stock [Member]	Note Payable Warrants [Member] Common Stock [Member]	Note Payable Warrants [Member] Additional Paid-in Capital [Member]	Note Payable Warrants [Member] Retained Earnings [Member]	Note Payable Warrants [Member] AOCI Attributable to Parent [Member]	Note Payable Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2016																																																																																																							$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Balance (in shares) at Dec. 31, 2016																																																																																																						79,246		4,564,428
Shares issued pursuant to the public offering				$ 1,750	$ 392,000			$ 393,750			$ 12,138		$ 1,201,681			$ 1,213,819																				$ 500	$ 78,500			$ 79,000																																																																$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)				175,000					1,213,819																											50,000																																																																				1,750,000
Vesting Expense																																																																																																									2,298,680			2,298,680
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																																																																								$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																																																																								(400,000)
Shares issued for services																				$ 1,000	$ 219,000			$ 220,000				$ 433	$ 63,699			$ 64,132
Shares issued for services (in shares)																				100,000								43,333
Unrealized (loss) from marketable securities																																																																																																										(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement																																																																																																							(5,659)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																																																																					(566,000)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																																																																								660,522
Preferred conversion to common shares pursuant to a private placement agreement																																																																																																								$ 6,604	85,236			86,182
Net loss																																																																																																										(6,003,017)		(6,003,017)
Balance at Dec. 31, 2017																																																																																																							7,271	$ 69,432	55,636,680	(53,021,469)		2,691,914
Balance (in shares) at Dec. 31, 2017																																																																																																					647,819	79,246		6,943,283
Shares issued pursuant to the public offering				$ 2,153	$ 202,268	$ 1		$ 204,422																																																																																																$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)				215,247																																																																																																				2,900,000
Vesting Expense																																																																																																									1,124,928			1,124,928
Shares issued for services																																												$ 1,500	$ 175,500			$ 177,000				$ 1,000	$ 117,000			$ 118,000
Shares issued for services (in shares)																																												150,000								100,000
Preferred conversion to common shares pursuant to a private placement agreement																																																																																																							(6,479)					(6,479)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																																																																					(647,819)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																																																																								589,747
Preferred conversion to common shares pursuant to a private placement agreement																																																																																																								$ 5,897	582
Net loss																																																																																																										(10,086,477)		(10,086,477)
Balance at Dec. 31, 2018																																																																																																							792	$ 140,917	63,019,708	(63,107,945)		53,472
Balance (in shares) at Dec. 31, 2018																																																																																																						79,246		14,091,748
Investment in Subsidiary pursuant to Helomics 20% acquisition																																																																				$ 11,000	$ 1,031,250			$ 1,042,250
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																																																																				1,100,000
Warrant exercises																																																																												$ 1,454	$ 143,942			$ 145,396				$ 5,046	$ 499,619			$ 504,665
Warrant exercises (in shares)																																																																												145,396								504,666
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share																																																												$ 7,500	$ 870,000			$ 877,500
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares)																																																												750,000
Debt Discount on Warrants																																																																																											$ 183,187			$ 183,187			$ 68,757			$ 68,757
Shares issued as inducement for Bridge Loan																																																																																																								$ 6,500	200,105			206,605
Shares issued as inducement for Bridge Loan (in shares)																																																																																																								650,000
Shares issued to employee in lieu of bonus																																																																																																								$ 435	$ 39,803			$ 40,238
Shares issued to employee in lieu of bonus (in shares)																																																																																																								43,409